ESR-1150 HYDROCHLORIDE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C12H17BrN4.ClH
Molecular Weight	333.655
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CN(C)C1=CC=C(Br)C(N=C2NCCN2)=C1C

InChI

InChIKey=QTAUWYULRRTZNV-UHFFFAOYSA-N

InChI=1S/C12H17BrN4.ClH/c1-8-10(17(2)3)5-4-9(13)11(8)16-12-14-6-7-15-12;/h4-5H,6-7H2,1-3H3,(H2,14,15,16);1H

HIDE SMILES / InChI

Molecular Formula	C12H17BrN4
Molecular Weight	297.194
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 00:36:48 GMT 2023` Edited by `admin` on `Sat Dec 16 00:36:48 GMT 2023`
Record UNII	P2BY9PUC48
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ESR-1150 HYDROCHLORIDE

Common Name

English

1,3-BENZENEDIAMINE, 4-BROMO-N3-(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)-N1,N1,2-TRIMETHYL-, HYDROCHLORIDE (1:1)

Systematic Name

English

4-BROMO-3-(IMIDAZOLIDIN-2-YLIDENEAMINO)-N,N,2-TRIMETHYL-ANILINE HYDROCHLORIDE

Systematic Name

English

ESR 1150CL

Code

English

Code System Code Type Description

CAS

850715-60-5

Created by admin on Sat Dec 16 00:36:48 GMT 2023 , Edited by admin on Sat Dec 16 00:36:48 GMT 2023

PRIMARY

PUBCHEM

140120264

Created by admin on Sat Dec 16 00:36:48 GMT 2023 , Edited by admin on Sat Dec 16 00:36:48 GMT 2023

PRIMARY

FDA UNII

P2BY9PUC48

Created by admin on Sat Dec 16 00:36:48 GMT 2023 , Edited by admin on Sat Dec 16 00:36:48 GMT 2023

PRIMARY

CLINICAL_TRIALS.GOV

ESR-1150-CL

Created by admin on Sat Dec 16 00:36:48 GMT 2023 , Edited by admin on Sat Dec 16 00:36:48 GMT 2023

PRIMARY

Official Title: Administration of ESR 1150 CL in Ascending Doses of 0.5, 1, 2, 4 and 8 mg in an Open, Group Comparison and Placebo-controlled Design (Placebo Randomised Double Blind in the Dose Groups) for the Assessment of Safety, Tolerability (Maximum Tolerated Dose, MTD), Pharmacokinetics and Pharmacodynamics in 5 Groups of 8 Female and 5 Male Healthy Subjects, and 4 mg Additionally in Fed State, in a Cross Over Design. Safety, Tolerability and Pharmacokinetics of MTD/4, MTD/2 and MTD in 6 Healthy Male Subjects, Identified as CYP2D6 and/or "Spartein" Poor Metabolizers, in a 3-fold Cross Over, Open Study.